Malaysia to Mandate Early Reporting of Drug Shortages from July 2026 to Strengthen Supply Resilience
KUALA LUMPUR: Malaysia will introduce a new requirement compelling pharmaceutical companies to report potential drug shortages at least six months in advance starting July 1, 2026, as part of a broader strategy to enhance national healthcare supply resilience.
Health Minister Dzulkefly Ahmad said the move marks a shift from reactive crisis management to a more proactive risk-based approach, reflecting ongoing global uncertainties affecting medical supply chains.
The system will be implemented through the National Pharmaceutical Regulatory Agency, requiring product registration holders (PRHs) to provide early notification of potential supply disruptions or discontinuations.
“This approach enables us to anticipate risks and take preventive action before shortages impact healthcare services,” he said.
Currently voluntary, the reporting framework will become mandatory to ensure better preparedness and continuity of supply.
Proactive Strategy to Address Global Risks
Dzulkefly said industry players have been given until mid-April to submit feedback on the availability of active pharmaceutical ingredients and packaging materials.
Such information is critical for early detection of risks and timely intervention to prevent supply disruptions.
He noted that supply chain stress often emerges as a delayed effect of crises, with internal simulations indicating disruptions could last at least six months.
As a result, the Ministry of Health is adopting a forward-looking approach, maintaining preparedness beyond immediate geopolitical developments.
Strengthening Stockpiles and Diversifying Sources
To safeguard supply, Malaysia is reinforcing its buffer stock system through a tiered approach, ensuring one to three months of supply at healthcare facilities, along with additional reserves at the concession level.
At the same time, efforts are underway to diversify import sources to reduce reliance on any single market.
The Medical Device Authority has also introduced rapid response mechanisms, including special access pathways to expedite procurement of critical medical devices during emergencies.
Data-Driven Management and Long-Term Strategy
Dzulkefly emphasised that stock management is guided by data-driven strategies to minimise waste, drawing lessons from the COVID-19 pandemic.
Rather than excessive stockpiling, the government is adopting a targeted and efficient approach to ensure the right supplies are available at the right time.
Reserve stocks will only be deployed in specific scenarios, such as major supply disruptions, operational delays, or public health emergencies.
Looking ahead, Malaysia aims to build a more self-reliant healthcare ecosystem by strengthening domestic production of active pharmaceutical ingredients and essential medicines.
This effort is supported by the national medicine security policy under MyMedSecure, which seeks to reduce dependency on imports.
Overall, the initiative reflects a comprehensive effort to ensure the healthcare system remains resilient, responsive, and well-prepared to navigate future global challenges.
-wilayah.com.my
